Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
Foresight Diagnostics Founders Respond to Roche Lawsuit, Says Claims Asserted in Bad Faith
Foresight said that Roche's asserted trade secrets were not secret and that the technologies at the heart of the claim are fundamentally different.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
Tethis, Weill Cornell Partner for CTC, cfDNA Analysis of Blood Samples in Early Breast Cancer
Weill Cornell researchers will use Tethis' platform to prepare blood samples for cell-free DNA and circulating tumor cell analysis.
Foresight Diagnostics Adds $33M to Series B Financing Round
The company has now raised $73.8 million in the round and plans to use the new funding to advance development of its Clarity minimal residual disease assay.